RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.


 

 

 

RAPS Highlights

 

 

 

 

25 May 2022 | By Ferdous Al-Faruque
Medtech groups want more time to implement FDA’s QMSR rule

Medical device lobby groups say they support the US Food and Drug Administration’s plan to align its Quality System Regulations (QSR...

25 May 2022 | By Mary Ellen Schneider
FDA issues Q&A on importation of prescription drugs from Canada

The US Food and Drug Administration (FDA) has offered some clarity on the legal requirements for small entities to import prescripti...

25 May 2022 | By Jeff Craven
House GOP reps question FDA commissioner on drugs with China-only data, trial site inspections

Republicans in the House Committee on Energy and Commerce have sent a letter to US Food and Drug Administration (FDA) Commissioner R...

25 May 2022 | By Michael Mezher
Recon: Teva, Allergan reach $161.5M opioid settlement with W. Virginia; Pfizer pledges to sell drugs at no profit in low-income countries

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.